Tech Company Financing Transactions
Aviceda Therapeutics Funding Round
Aviceda Therapeutics, based in Cambridge, secured $207.5 million in investment from Omega Funds, TCGX and Blue Owl Capital.
Transaction Overview
Company Name
Announced On
1/8/2025
Transaction Type
Venture Equity
Amount
$207,500,000
Round
Series C
Investors
Omega Funds (Lead Investor)
TCGX (Lead Investor)
Proceeds Purpose
The company intends to use the funds to support the ongoing Phase 2b/3 and planned pivotal Phase 3 clinical trial for AVD-104 in geographic atrophy (GA), a vision-threatening condition secondary to advanced age-related macular degeneration, and the expansion into other ophthalmic indications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Cambridge, MA Undisclosed
USA
Cambridge, MA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Aviceda Therapeutics, a Cambridge, MA-based private, clinical-stage biotech company focused on developing new immunomodulators.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
David Guyer
Browse more venture capital transactions:
Prev: 1/8/2025: VitVio venture capital transaction
Next: 1/8/2025: 360 Advanced venture capital transaction
Share this article
News on VC Transactions
We do our best to document every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs